Clinical assessment of therapeutic effects on cancer using 18F-2-fluoro-2-deoxy-d-glucose and positron emission tomography: Preliminary study of lung cancer

Oncological applications of positron emission tomography with fluorine-18 fluorodeoxyglucose

“…Experience is also available regarding the use of PET to assess lung tumour response to therapy and in the detection of recurrences after successful initial therapy. Abe et al [124] demonstrated that patients judged to have a clinically complete response to radiotherapy or chemo-therapy had negative PET results while results remained positive in patients with a partial response. Knopp [124,125].…”

“…Abe et al [124] demonstrated that patients judged to have a clinically complete response to radiotherapy or chemo-therapy had negative PET results while results remained positive in patients with a partial response. Knopp [124,125]. Others have also reported a high diagnostic accuracy of FDG PET in the detection of tumour recurrence [113,[126][127][128][129][130].…”

Carbon-11-methionine and PET in evaluation of treatment response of breast cancer

“…The differences in the tumour blood flow (Abe et al, 1990), physiological circumstances such as the body temperature, the location of the tumour in the field and the complex metabolism of methionine (Hoffman, 1984) should be beared in mind when interpreting the results of PET studies. The error marginal in PET studies is approximately 5% (Spinks et al, 1988).…”

“…Positron emission tomography (PET) has opened a totally new approach in evaluating metabolical changes in cancer tissue caused by chemotherapy or radiotherapy in vivo. Using a glucose analogue '8F-2-fluoro-2-deoxy-D-glucose (FDG) and PET imaging may be a valuable method in predicting treatment response in head and neck cancer (Minn et al, 1988), breast cancer (Minn & Soini, 1989) and lung cancer (Abe et al, 1990). Active metabolism may be visualised by radiotracers such as FDG or L-methyl-"C-methionine ("C-methionine) which take part in altered turnover of glucose or amino acids in cancer tissue (Kubota et al, 1985;Wahl et al, 1991).…”

Pioneering and Fundamental Achievements on the Development of Positron Emission Tomography (PET) in Oncology

“…The decrease and increase of tumor 18 F-FDG uptake after irradiation well correlated with tumor volume changes. Abe et al (1990) first evaluated the 18 F-FDG uptake of the human lung cancer before and after irradiation and showed that 18 F-FDG can be used for the assessment of radio-therapeutic effectiveness in the clinical setting. Kubota et al (1989b) examined the effects of radiation on 11 C-MET uptake by tumors.…”